PD14-04 INTERRUPTIONS IN BLADDER CANCER CARE DURING THE COVID-19 PUBLIC HEALTH EMERGENCY

Abstract

You have accessJournal of UrologyCME1 May 2022PD14-04 INTERRUPTIONS IN BLADDER CANCER CARE DURING THE COVID-19 PUBLIC HEALTH EMERGENCY Jason Reynolds, Kristin Follmer, Michael Nash, On Ho, Bryan Comstock, Larry Kessler, Erika Wolff, Angela Smith, John Gore, and CISTO Collaborative Jason ReynoldsJason Reynolds More articles by this author , Kristin FollmerKristin Follmer More articles by this author , Michael NashMichael Nash More articles by this author , On HoOn Ho More articles by this author , Bryan ComstockBryan Comstock More articles by this author , Larry KesslerLarry Kessler More articles by this author , Erika WolffErika Wolff More articles by this author , Angela SmithAngela Smith More articles by this author , John GoreJohn Gore More articles by this author , and CISTO Collaborative More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002546.04AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: The COVID-19 pandemic has impacted various clinical and research processes in urologic care. As part of a pragmatic clinical trial in bladder cancer, we collected information regarding the impact of COVID-19 at participating sites, which provides insight into how the pandemic has imposed constraints on clinical bladder cancer care and research. METHODS: Starting in May 2020, we distributed a monthly survey to sites participating in CISTO (Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer, NCT0393382). The survey included questions about interruptions in routine clinical bladder cancer care, specifically assessing elective surgery restrictions, impact on radical cystectomy, TURBT, office cystoscopies, intravesical therapy, and intravesical bacillus Calmette-Guerin (BCG) supply. We report survey responses for sites that responded to > 50% of the monthly surveys from May 2020 to October 2021. RESULTS: From May 2020 through October 2021, 21 sites (66%) had > 50% monthly response rate. The time periods of greatest limitations on bladder cancer procedures (Figure 1) were May-July 2020, Dec-Jan 2020/2021, and Sept-Oct 2021, corresponding to the peak waves of COVID-19 infections. Elective surgery was most affected, with limitations or holds in those time periods at up to 76%, 38%, and 28% of CISTO sites, respectively. Most of the restrictions involved surgeries that required inpatient stays, potential intensive care unit admission, and staffing shortages. 9 sites (28%) experienced transient BCG shortages during the survey period. CONCLUSIONS: Clinical activity was most limited during the initial COVID-19 surge in Spring/Summer 2020. Despite higher COVID-19 infection rates in subsequent waves, bladder cancer clinical activity has been maintained at CISTO sites throughout the COVID pandemic. Periodic BCG shortages continue to affect bladder cancer care across the US. Source of Funding: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer, NCT0393382 © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 207Issue Supplement 5May 2022Page: e257 Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.MetricsAuthor Information Jason Reynolds More articles by this author Kristin Follmer More articles by this author Michael Nash More articles by this author On Ho More articles by this author Bryan Comstock More articles by this author Larry Kessler More articles by this author Erika Wolff More articles by this author Angela Smith More articles by this author John Gore More articles by this author CISTO Collaborative More articles by this author Expand All Advertisement PDF DownloadLoading ...